Blueshift Asset Management LLC Buys 218,804 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Blueshift Asset Management LLC increased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 834.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 245,013 shares of the company's stock after acquiring an additional 218,804 shares during the period. Hims & Hers Health comprises about 1.1% of Blueshift Asset Management LLC's holdings, making the stock its 9th largest holding. Blueshift Asset Management LLC owned approximately 0.11% of Hims & Hers Health worth $4,513,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of HIMS. Nisa Investment Advisors LLC lifted its stake in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock worth $37,000 after acquiring an additional 1,603 shares in the last quarter. Quest Partners LLC lifted its stake in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after acquiring an additional 3,507 shares in the last quarter. CWM LLC lifted its stake in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after acquiring an additional 1,054 shares in the last quarter. Van ECK Associates Corp purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth about $111,000. Finally, Amalgamated Bank raised its stake in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company's stock worth $133,000 after purchasing an additional 2,354 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Trading Down 1.1 %

HIMS traded down $0.34 during midday trading on Wednesday, reaching $30.34. The company's stock had a trading volume of 24,568,938 shares, compared to its average volume of 9,806,393. The stock has a market cap of $6.63 billion, a P/E ratio of 68.96 and a beta of 1.06. The company has a fifty day simple moving average of $21.14 and a 200 day simple moving average of $19.57. Hims & Hers Health, Inc. has a twelve month low of $8.09 and a twelve month high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's revenue was up 77.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.04) EPS. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HIMS. Bank of America downgraded Hims & Hers Health from a "buy" rating to an "underperform" rating and cut their price target for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Needham & Company LLC began coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a "buy" rating and a $24.00 price target for the company. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research note on Wednesday, November 6th. Canaccord Genuity Group raised their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Finally, Imperial Capital downgraded Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $20.71.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50. Following the sale, the insider now owns 176,952 shares of the company's stock, valued at approximately $2,919,708. This trade represents a 1.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anja Manuel purchased 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The stock was bought at an average cost of $26.94 per share, for a total transaction of $107,760.00. Following the purchase, the director now owns 4,000 shares in the company, valued at $107,760. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 1,153,519 shares of company stock valued at $24,486,721. 17.71% of the stock is owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.